



26.02.2024

08:30 - 12:00 **Type: Educational session** **Room 341**
Title: MDICT

08:30 - 08:35 **Welcome**
Lesley Seymour, Canadian Cancer Trials Group, Kingston, Canada

08:35 - 08:50 **Overview of NeoECT**
Christophe Le Tourneau, Institut Curie, Paris, France

08:50 - 09:00 **Key challenges to be addressed**
Anastasios Stathis, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland

09:00 - 10:35 **Break out sessions & coffee break**

10:35 - 11:00 **Key feedback from breakouts**

11:00 - 12:00 **Recommendation development**

12:15 - 13:00 **Type: Break** **Hall Bordeaux**
Title: Welcome reception

13:00 - 13:40 **Type: Keynote address** **Amphitheatre Bordeaux**
Title: Welcome to ESMO TAT 2024 and Honorary Award
Moderation: Elena Garralda, Spain; Lillian Siu, Canada; Anastasios Stathis, Switzerland

13:00 - 13:08 **Welcome to ESMO TAT 2024**
Elena Garralda¹, Lillian Siu², Anastasios Stathis³, ¹Vall d'Hebron University Hospital, Barcelona, Spain, ²Princess Margaret Cancer Centre, Toronto, Canada, ³EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland

13:08 - 13:15 **Introduction to the 2024 TAT Honorary Award keynote lecture**
Elena Garralda, Vall d'Hebron University Hospital, Barcelona, Spain

13:15 - 13:40 **Implementing precision oncology: From genomics to ADCs**
Funda Meric-Bernstam, The University of Texas M. D. Anderson Cancer Center, Houston, United States of America



13:45 - 15:15	Type: Special session with Industry Title: Oncology drug development: Biotech status and prospects Moderation: Giovanni Abbadessa, United States of America; Anastasios Stathis, Switzerland	Amphitheatre Bordeaux
13:45 - 13:55	Introduction <u>Giovanni Abbadessa</u> , Sanofi, Cambridge, United States of America	
13:55 - 14:10	The small Biotech perspective <u>Filip Janku</u> , Monte Rosa Therapeutics, Inc., Boston, United States of America	
14:10 - 14:25	The Investor perspective <u>Yael Gruenbaum Cohen</u> , aMoon Ventures Sh.Y.Ltd, Ra'anana, Israel	
14:25 - 14:40	The Academia perspective <u>Christophe Le Tourneau</u> , Institut Curie, Paris, France	
14:40 - 15:15	Panel discussion <u>All Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, Switzerland	
15:15 - 15:45	Type: Break Title: Coffee break	Hall Bordeaux



15:45 - 17:15	Type: Abstract session Title: Abstract session 1 Moderation: Capucine Baldini, France; Irene Braña, Spain; Alastair Greystoke, United Kingdom	Amphitheatre Bordeaux
15:45 - 15:53	250 - Phase I tolerability, persistence and pharmacodynamic (PD) profile of IV-administered next-generation adenoviral vectors supports clinical expansion in solid cancers <u>Danny Khalil</u> , Memorial Sloan Kettering Cancer Center, New York, United States of America	
15:53 - 16:01	260 - Phase I dose-escalation trial with tumor-targeted interleukin-12 (IL12-L19L19) in patients with solid tumors <u>Giuseppe Curigliano</u> , IEO - Istituto Europeo di Oncologia, Milan, Italy	
16:01 - 16:11	Invited discussant abstracts 250 and 260 <u>Capucine Baldini</u> , Institut Gustave Roussy, Villejuif, Cedex, France	
16:11 - 16:19	430 - A dose-escalation study of TNO155 (TN) in combination with spartalizumab (SPA) or ribociclib (RIB) in adults with advanced solid tumors <u>Omar Saavedra Santa Gadea</u> , Vall d'Hebron Institute of Oncology, Barcelona, Spain	
16:19 - 16:27	440 - Updated results from a phase I study evaluating the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC <u>Carlos Rojas</u> , Centro de Investigacion Clinica, Bradford Hill, Santiago, Chile	
16:27 - 16:37	Invited discussant abstracts 430 and 440 <u>Alastair Greystoke</u> , Newcastle University, Newcastle upon Tyne, United Kingdom	
16:37 - 16:45	450 - First-in-human study of ABSK061: A selective fibroblast growth factor receptor (FGFR) 2/3 inhibitor for treating patients with advanced solid tumors <u>Ji Zhu</u> , Zhejiang Cancer Hospital, Hangzhou, China	
16:45 - 16:53	270 - Interim results of a phase I/II trial of NT219 in combination with cetuximab in patients with advanced/metastatic squamous cell carcinoma of the head and neck (SCCHN) <u>Ari Rosenberg</u> , University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, United States of America	
16:53 - 17:03	Invited discussant abstracts 450 and 270 <u>Irene Braña</u> , Vall d'Hebron University Hospital, Barcelona, Spain	
17:03 - 17:15	Q&A <u>All Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, Switzerland	



17:15 - 18:15	Type: Poster Display session Title: Cocktail and Poster Display session	Hall Bordeaux
	Moderation: Giuseppe Curigliano, Italy; Elena Garralda, Spain; Donna Graham, United Kingdom; Melissa Johnson, United States of America; Juanita Lopez, United Kingdom; Lesley Seymour, Canada; Anastasios Stathis, Switzerland; Daniel Shao Weng Tan, Singapore	
17:15 - 17:15	AI and digital therapeutics	
17:15 - 17:15	2P - A machine learning-powered dashboard for the exploration of high-throughput transcriptomic datasets <u>Valentin Bernu</u> , Epigene Labs, Paris, France	
17:15 - 17:15	3P - Evaluating conversational generative pre-trained transformer (ChatGPT) as a tool in early breast cancer (eBC) cases <u>Francesca Patanè</u> , AOU Pisana - Stabilimento di Santa Chiara, Pisa, Italy	
17:15 - 17:15	4P - Integrative epigenomics and transcriptomics analysis to identify signature biomarkers of lung adenocarcinoma <u>Arnab Mukherjee</u> , MAHE - Manipal Academy of Higher Education, Manipal, India	
17:15 - 17:15	5P - Using AI and clinical knowledge to find missed lung and ovarian cancer patients <u>Vibhor Gupta</u> , Pangaea Data Limited, London, United Kingdom	
17:15 - 17:15	Antibody-based therapies	
17:15 - 17:15	7P - Molecular targeted therapies based on metastatic site in first-line treatment for colorectal cancer patients: An ARCAD pooled analysis <u>Morteza Raeisi</u> , ARCAD Foundation, Paris, France	
17:15 - 17:15	8P - Factors associated with primary progression in patients with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV): Analysis of the UNITE study <u>Tanya Jindal</u> , UCSF - University of California San Francisco, San Francisco, United States of America	
17:15 - 17:15	9P - The efficacy of HIF-1 alpha expression in the response to first-line standard chemotherapy and bevacizumab treatment in patients diagnosed with metastatic cervical cancer <u>Hasan Yildirim</u> , Hacettepe University Oncology Hospital, Ankara, Turkey	
17:15 - 17:15	10P - Treatment of vaginal cancer by suppression of inhibitory receptors of CD8 T cell in mouse model <u>Dong Choon Park</u> , The Catholic University of Korea - St. Vincent's Hospital, Suwon, Korea, Republic of	



- 17:15 - 17:15 **11P - snRNP200 reactive antibodies isolated from multiple AML patients show promise for targeted therapy**
Sebastian Baumann, Kling Biotherapeutics, Amsterdam, Netherlands
- 17:15 - 17:15 **12P - KBA1413, an antibody derived from a cured AML patient, recognizes a unique CD43 glycoform shared by AML, MDS and solid cancer cells**
Vanessa Clerico Mosina, Kling Biotherapeutics, Amsterdam, Netherlands
- 17:15 - 17:15 **13P - Raising anti-MUC-1 antibodies with a novel immunization platform based on the African trypanosome**
Anastasia Gkeka, Panosome GmbH, Heidelberg, Germany
- 17:15 - 17:15 **14P - Kling-Select and Kling-Evolve: A universal platform interrogating blood and tumor-associated B cell repertoires enabling unbiased discovery of therapeutic targets and antibodies from patients**
Casper Marsman, Kling Biotherapeutics, Amsterdam, Netherlands
- 17:15 - 17:15 **DNA damage repair and epigenetics**
- 17:15 - 17:15 **16P - VIO-01, a pan-DDR DNA decoy triggering DNA repair abrogation and an enhanced antitumor immune response**
Wael Jdey, Valerio Therapeutics, Paris, France
- 17:15 - 17:15 **17P - Homologous recombination deficiency status in consecutive tumor biopsies in late-stage cancer patients**
Rosa Damkjær Britton, Rigshospitalet, Copenhagen, Denmark
- 17:15 - 17:15 **18P - NEK1 is a novel cancer target driving tumor growth through altered immune signaling**
Maria Victoria Ruiz Perez, Turbine kft - Turbine Simulated Cell Technologies Ltd., Budapest, Hungary
- 17:15 - 17:15 **19P - Pharmacodynamic activity of [18F]-fluorothanatrace poly(ADP-ribose) polymerase (PARP) PET in BRCA1/2-mutated breast cancer patients receiving talazoparib**
Lilie Lin, The University of Texas MD Anderson Cancer Center - Main Building, Houston, United States of America
- 17:15 - 17:15 **20P - Investigating the effects of epigenetic editing of cancer-specific differentially methylated genomic regions on breast cancer cell growth, clonogenicity, and invasiveness**
Sarah Mungly, Sunway University, Bandar Sunway, Malaysia
- 17:15 - 17:15 **21P - Polymerase theta inhibition in homologous recombination-deficient prostate cancer**



Lucia Nappi, UBC - The University of British Columbia, Vancouver, Canada

- 17:15 - 17:15 **22P - Platinum resistance development in high grade serous ovarian carcinoma: Exploring epigenetic alterations as potential drivers of resistance in ovarian cancer relapse at transcriptomic level**
Raffaella Ergasti, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, Italy
- 17:15 - 17:15 **23P - Antimetastatic potential of lncRNA group in ovarian carcinoma**
Svetlana Lukina, FSBSI Institute of General Pathology and Pathophysiology, Moscow, Russian Federation
- 17:15 - 17:15 **24P - New hybrid camptothecin-based molecules: Promising antitumor agents for the treatment of hematological malignancies**
Lilya Dzhemileva, FSBI National Medical Research Center of Endocrinology of the Ministry of Health of Russia, Moscow, Russian Federation
- 17:15 - 17:15 **Immunotherapy**
- 17:15 - 17:15 **30P - OSE279, a PD-1-blocking monoclonal antibody, as future backbone of a bifunctional checkpoint inhibitor platform: Preliminary results of a first-in-human (FIH) study in subjects with advanced malignancies**
Marie Robert, Institut de Cancérologie de l'Ouest, Saint-Herblain, France
- 17:15 - 17:15 **32P - Validation of the Scottish Immunotherapy Prognostic Score (SIPS) in NSCLC patients treated with first-line pembrolizumab**
Martin Igor Gomez-Randulfe Rodriguez, The Christie NHS Foundation Trust, Manchester, United Kingdom
- 17:15 - 17:15 **33P - A phase IV study of EXTREME regimen versus nivolumab plus paclitaxel and cisplatin/carboplatin-based regimen in recurrent or metastatic squamous cell carcinoma of the head and neck**
Avinash Khadela, L. M. College of Pharmacy, Ahmedabad, India
- 17:15 - 17:15 **34P - Cocktail peptide vaccines targeting cancer stem cells for enhanced therapeutic efficacy in oral cancers**
Sho Miyamoto, Sapporo Medical University School of Medicine, Sapporo, Japan
- 17:15 - 17:15 **35P - Beyond microsatellite testing: Tumor mutational burden, should it be routine in patients with GI cancers?**
Farrukh Djuraev, Tashkent Medical Park, Tashkent, Uzbekistan
- 17:15 - 17:15 **36P - Development of patient-derived explant model as a robust preclinical tool to predict the efficacy of ICB-based immunotherapy in colorectal cancer patients**
Hayet Rafa, University of Sciences and Technology Houari Boumedienne - Faculty of biological sciences, Algiers, Algeria



- 17:15 - 17:15 **37P - Efficacy and safety of PD-1 monoclonal antibodies in the treatment of esophageal squamous cell carcinoma: Systematic review and meta regression analysis**
Ameer Al Wssawi, Al-Qadiysiah University - College of Medicine, Al Diwanayah, Iraq
- 17:15 - 17:15 **39P - The possibility of predicting the effectiveness of treatment of soft tissue sarcomas on the basis of the properties of their immunologic microenvironment**
Nuriddin Asamedinov, Tashkent State Dental Institute, Tashkent, Uzbekistan
- 17:15 - 17:15 **40P - Small molecule inhibitor HI-TOPK-032 improves NK-92MI cells infiltration into ovarian tumors**
Ruiye Yang, Beijing Obstetrics and Gynecology, Capital Medical University, Beijing, China
- 17:15 - 17:15 **41P - Unveiling the complex interplay of B7-H3, oxylipins, and immune responses in ovarian cancer microenvironment**
Mengqi Deng, Beijing Obstetrics and Gynecology Hospital, Capital Medical University - East Courtyard, Beijing, China
- 17:15 - 17:15 **42P - sONE and MEG3: Novel immunomodulatory tumor suppressor LncRNAs in HCV-induced hepatocellular carcinoma patients**
Rana Youness, German International University, Cairo, Egypt
- 17:15 - 17:15 **Kinase-targeting agents and cell signalling modulators**
- 17:15 - 17:15 **46P - Dynamics of ROS1 kinase binding: Insights into DFG-out tyrosine kinase inhibitors and effects of allosteric-pocket mutations**
Farhan Haq, University of Antwerp, Edegem, Belgium
- 17:15 - 17:15 **47P - Unlocking potential for enhancing anti-tumor immunity: Targeting hematopoietic progenitor kinase 1 (HPK1) with novel small molecules**
Sreevalli Sharma, Bugworks Research India Pvt. Ltd., Bengaluru, India
- 17:15 - 17:15 **48P - BWC5044 is a novel potent and highly selective CDK7 inhibitor that suppresses transcriptional activity and arrests the cell cycle through MYC**
Sonali Setua, Bugworks Research India Pvt. Ltd., Bengaluru, India
- 17:15 - 17:15 **49P - Computational approaches for the development of cyclin-dependent kinase 1 inhibitors as anti-cancer compounds**
Vineeta Teotia, Delhi University - North Campus, New Delhi, India
- 17:15 - 17:15 **50P - Comparison of pelitinib, tepotinib, and docetaxel efficacy according to the copy number or gene alteration status of the EGFR, MET, HRAS, KRAS, and NRAS genes**
Dae Young Zang, HUMC - Hallym University Sacred Heart Hospital (HUSHH), Anyang, Korea, Republic of



- 17:15 - 17:15 **51P - Discovery of novel CDK12/13 inhibitors as cyclin K molecular glues targeting metastatic breast and gastric cancer**
Anna Moon, iLeadBMS Co., Ltd., Hwaseong, Korea, Republic of
- 17:15 - 17:15 **52P - miRNA-based therapeutics for triple-negative breast cancer**
Bulent Ozpolat, Houston Methodist Research Institute, Houston, United States of America
- 17:15 - 17:15 **53P - PHI-501 as a potent pan-RAF/DDR2 inhibitor suppresses colorectal cancer cell proliferation and overcomes BRAF inhibitor resistance**
Sue Min Kim, Yonsei University College of Medicine, Seoul, Korea, Republic of
- 17:15 - 17:15 **54P - Resistance to MAPK pathway inhibition in BRAF-V600E mutant colorectal cancer can be overcome with insulin receptor/insulin-like growth factor-1 receptor inhibitors**
Layla El Bouazzaoui, UMC - University Medical Center Utrecht, Utrecht, Netherlands
- 17:15 - 17:15 **55P - High snail expression and activation of mTOR promote liver recurrence after hepatic metastasectomy for colorectal cancer**
Seçil Aksoy, Bursa Uludag University - Faculty of Medicine, Bursa, Turkey
- 17:15 - 17:15 **56P - Rapid and accurate prediction of TKI treatment response in advanced EGFR-mutant non-small cell lung cancer using the CODRP platform**
Chan Kwon Park, The Catholic University of Korea - College of Medicine - Yeouido St. Mary's Hospital, Seoul, Korea, Republic of
- 17:15 - 17:15 **57P - The role of mir29-a and mir143 on the anti-apoptotic MCL-1/cIAP-2 genes expression in EGFR mutated non-small cell lung carcinoma patients**
Zahra Abrehdari-Tafreshi, School of Biology, College of Sciences, University of Tehran, Tehran, Iran
- 17:15 - 17:15 **58P - Novel nanoACPA delivery system presents antitumor effect on ectopic non-small cell lung cancer xenograft model**
Ozge Boyacioglu, Hacettepe University & Atılım University, Ankara, Turkey
- 17:15 - 17:15 **59P - Evaluating anticancer drug sensitivity in ALK-rearrangement-positive non-small cell lung cancer using the CODRP index-based test**
Seung Joon Kim, The Catholic University of Korea - Seoul St. Mary's Hospital - Catholic Medical Center, Seoul, Korea, Republic of
- 17:15 - 17:15 **60P - Impact of eIF6 on BRAF inhibitor resistance and translation dynamics in cutaneous melanoma**
George Kyriakopoulos, University of Patras, Patras, Greece
- 17:15 - 17:15 **61P - Genes affecting the sensitivity to the copanlisib/venetoclax combination in lymphoma cells identified via genetic screen**



Sara Napoli, Institute of Oncology Research, Bellinzona, Switzerland

17:15 - 17:15

62P - Phase I/II study of pazopanib and temozolomide in patients with newly diagnosed glioblastoma multiforme: PAZOGLIO trial

Esma Saada, CAL, NICE, France

17:15 - 17:15

63P - Activity and safety of FGFR inhibitors in pan-cancer patients with FGF/FGFR alterations and advanced malignancies: A pooled analysis of 7 phase I/II trials

Rafael Grochot, Sarah Cannon Research Institute SCRI UK, London, United Kingdom

17:15 - 17:15

64P - LX-101, a novel, clinical stage, payload-bearing IGF-1R targeted therapy, demonstrates activity in patients with high IGF-1R tumor expression

Arkadiusz Dudek, Mayo Clinic, Rochester, United States of America

17:15 - 17:15

65P - Preliminary results of a phase II multicenter, open-label study of fruquintinib monotherapy as third-line treatment in advanced pancreatic cancer

Weijian Guo, Fudan University Affiliated Cancer Hospital, Shanghai, China

17:15 - 17:15

66P - Analysis of the safety and effectiveness of TACE combined with donafenib in the treatment of intermediate and advanced hepatocellular carcinoma

Jinlong Song, Shandong Cancer Hospital and Institute, Jinan, China

17:15 - 17:15

67P - Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma

Hasan Yildirim, Hacettepe University Oncology Hospital, Ankara, Turkey

17:15 - 17:15

68P - Real-world clinical and treatment-related outcomes in specific subgroups of patients with BRAF-positive metastatic melanoma treated with dabrafenib-trametinib: Turkish Oncology Group study

Eda Caliskan Yildirim, Dokuz Eylul University School of Medicine - Institute of Oncology, Izmir, Turkey

17:15 - 17:15

69P - Deregulation of hippo pathway kinases in uveal melanoma: Implications for prognosis and therapeutic targets

Nikhil Kumar, AIIMS - All India Institute of Medical Sciences, New Delhi, Delhi, India

17:15 - 17:15

70P - Combination of EGFR-TKI and chemotherapy versus EGFR-TKI monotherapy as neoadjuvant treatment of stage III-N2 EGFR-mutant non-small cell lung cancer

Yingqi Xu, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

17:15 - 17:15

71P - The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: A Turkish Oncology Group (TOG) study

Hasan Yildirim, Hacettepe University Oncology Hospital, Ankara, Turkey



- 17:15 - 17:15 **72P - Prevalence and potential consequences of drug-drug interactions in oncohematological patients treated with oral antineoplastic drugs**
Eduard Fort, ICO - Institut Català d'Oncologia - Hospital Duran i Reynals, Hospitalet de Llobregat, Spain
- 17:15 - 17:15 **73P - Imatinib induced thyroid dysfunction in BCR::ABL1-positive chronic myeloid leukemia (CML) patients: Sokal score as a predictor**
Ibrahim Ahmed, Obafemi Awolowo University Teaching Hospital, Ile Ife, Nigeria
- 17:15 - 17:15 **Methodological, financial and regulatory aspects**
- 17:15 - 17:15 **75P - U-PRO-CRM: Designing patient-centred dose-finding trials with patient-reported outcomes**
Christina Yap, ICR - The Institute of Cancer Research - North Site, Sutton, United Kingdom
- 17:15 - 17:15 **76P - Utilization of g score in early oncology drug development: Impact on study design and early go/no-go decision**
Philip He, Daiichi Sankyo, Inc., Basking Ridge, United States of America
- 17:15 - 17:15 **77P - Experience pooling control arms within a complex phase I drug-radiotherapy (RT) platform trial**
Jamie Oughton, University of Leeds - Leeds Institute of Clinical Trials Research (LICTR), Leeds, United Kingdom
- 17:15 - 17:15 **78P - Implementing the modified partial order time-to-event continual reassessment method in a phase I ovarian cancer combination trial with unknown dosing ordering**
Xinjie Hu, The Institute of Cancer Research, Sutton, United Kingdom
- 17:15 - 17:15 **79P - Pharmaceutical cost savings for the treatment of oncology patients in clinical trials**
Borja Gómez-Mediavilla, IDIVAL - Instituto de Investigacion Sanitaria Valdecilla, Santander, Spain
- 17:15 - 17:15 **80P - Social determinants of health inequalities in early phase clinical trials in Northern England**
Sarah Rae, Newcastle University, Newcastle upon Tyne, United Kingdom
- 17:15 - 17:15 **81P - Early access program: The reality of a Portuguese oncology center**
Lisa Goncalves, HSM - Hospital Santa Maria - Centro Hospitalar Universitario de Lisboa Norte E.P.E., Lisbon, Portugal
- 17:15 - 17:15 **82P - Impact of compassionate access drugs in a low-middle income country such as India**



Naveen K, Tata Memorial Hospital - Parel, Mumbai, India

- 17:15 - 17:15 **83P - Cost-effectiveness analysis of talazoparib maintenance treatment for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US**
Qiaoping Xu, Hangzhou first people's hospital, Hangzhou, China
- 17:15 - 17:15 **84P - Applied methodology for measure selection using connected sensors to supplement commonly used quality of life clinical outcome assessments (COAs) and optimize safety review in oncology care**
Megan Parisi, Syneos Health - Corporate Headquarters, Morrisville, United States of America
- 17:15 - 17:15 **Molecular profiling applications**
- 17:15 - 17:15 **87P - Enhancing treatment strategies for metastatic high-grade neuroendocrine neoplasms: Insights from extensive genomic profiling through WES and WGS in a phase I clinical setting**
Sara Krogshede, Rigshospitalet, Copenhagen, Denmark
- 17:15 - 17:15 **88P - Circulating tumor DNA (ctDNA) as precision medicine marker for neoadjuvant chemotherapy vs upfront surgery in primary resectable localized pancreatic cancer**
Patrick Kirchweger, Ordensklinikum Linz GmbH - Barmherzige Schwestern, Linz, Austria
- 17:15 - 17:15 **89P - ctDNA as an unifiable biomarker to predict response to treatment after 2 weeks of chemotherapy at the same cut-off for metastatic GEC, PC and CRC**
Patrick Kirchweger, Ordensklinikum Linz GmbH - Barmherzige Schwestern, Linz, Austria
- 17:15 - 17:15 **90P - RAS mutant colorectal cancer in Portuguese tertiary care: Molecular landscape and patterns of metastatic spread**
José Mendes, Centro Hospitalar de Lisboa Central (CHLC)-Hospital de Santo António dos Capuchos (HSAC), Lisbon, Portugal
- 17:15 - 17:15 **91P - Prevalence of HR-/DDR-genes alterations across sarcoma histologies: Insights from a cBioPortal comprehensive analysis**
Luca Boscolo Bielo, European Institute of Oncology, Milan, Italy
- 17:15 - 17:15 **92P - Molecular/genomic profile enhances prediction of response to target therapy in HER2-positive breast cancer**
Daniel Tiezzi, HC-FMRP-USP - Hospital das Clínicas da Faculdade de Medicina de Ribeirão, Ribeirão Preto, Brazil
- 17:15 - 17:15 **93P - Evolving landscape of targeted therapies (TT) in early phase clinical trials (EPCT): The RESISTANCE project (360R)**
Alice Rossi, Vall d'Hebron University Hospital, Barcelona, Spain



- 17:15 - 17:15 **94P - Comprehensive screening for clinical study eligibility using whole genome sequencing**
Paul Roepman, Hartwig Medical Foundation, Amsterdam, Netherlands
- 17:15 - 17:15 **95P - Italian national policy to access molecular tumor boards: Opportunity or restraint for precision oncology?**
Edoardo Crimini, IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy
- 17:15 - 17:15 **96P - Use and utility of a genomic platform in daily care practice: A single center retrospective cohort**
Marco Gornatti, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
- 17:15 - 17:15 **98P - Cancers of unknown primary (CUP): Real-world clinical outcomes and genomic analysis at the European Institute of Oncology**
Luca Boscolo Bielo, European Institute of Oncology, Milan, Italy
- 17:15 - 17:15 **99P - Molecular correlates and treatment outcomes of patients with brain metastasis included in early phase trials: A single-center retrospective analysis**
Giulia Pretelli, Vall d'Hebron Institute of Oncology, Barcelona, Spain
- 17:15 - 17:15 **100P - Impact of IDH mutation and adjuvant chemo(radio)therapy on survival outcome in grade II/III astrocytoma**
Mohammad Hamad, IAU - The University of Jordan, Amman, Jordan
- 17:15 - 17:15 **101P - Galectin 3 binding protein signature as early detection biomarker of glioma**
Rashmi Rana, Sir Ganga Ram Hospital, New Delhi, India
- 17:15 - 17:15 **102P - A retrospective description of actionable mutations incidence within a comprehensive cancer genome profiling programme: Is less still more?**
Floriana Camarda, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- 17:15 - 17:15 **103P - Establishing a patient-derived tumour spheroid model using endoscopic biopsy specimens of gastrointestinal cancers**
Hironaga Satake, Kochi Medical School Hospital, Nankoku, Japan
- 17:15 - 17:15 **General interest**
- 17:15 - 17:15 **105P - Targeting the tRNA methyltransferase METTL1 with small molecule inhibitors in cancer**
Alexandra Sapetschnig, Storm Therapeutics Ltd, Cambridge, United Kingdom

17:15 - 17:15



106P - Optimisation of FAP-targeted small molecule drug conjugates for the delivery and release of cytotoxic payloads in solid tumors

Jacqueline Mock, Philochem AG, Otelfingen, Switzerland

17:15 - 17:15 **107P - Inhibition of hydrogen sulfide biosynthesis influences mitochondrial biogenesis in breast cancer**

Kareem Elsayed, GUC - German University in Cairo, New Cairo, Egypt

17:15 - 17:15 **108P - Targeting de novo lipogenesis synergizes with androgen-receptor inhibitors in castration-resistant prostate cancer**

Pier Vitale Nuzzo, Weill Cornell Medicine - Belfer Research Building, New York, United States of America

17:15 - 17:15 **109P - Artesunate induces ferroptosis and suppresses cell proliferation in ovarian cancer cells**

Yusanne Yung Sing Chan, HKU - The University of Hong Kong, Hong Kong, China

17:15 - 17:15 **110P - EGFR amplification is the potential driver gene that accelerates brain metastases in NSCLC patients**

Hainan Yang, Shanghai GoBroad Cancer Hospital, Shanghai, China

17:15 - 17:15 **111P - Reporting of late serious adverse drug reactions (ADRs) in drug labels of targeted anticancer agents**

Dimitar Stefanovski, Institute of Oncology Ljubljana, Ljubljana, Slovenia

17:15 - 17:15 **112P - Measuring time-toxicity and prognostic impact of hospital attendance in early phase cancer trials participants**

Nichola Awosika, Imperial College London - Hammersmith Campus, London, United Kingdom

17:15 - 17:15 **113P - The prognostic importance of nutrition and inflammation in advanced lung cancer with actionable mutation**

Dogan Bayram, Ankara City Hospital, Ankara, Turkey

17:15 - 17:15 **114P - Effects of chemotherapy on TREG lymphocytes in early breast cancer**

Sara Cresta, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

17:15 - 17:15 **115P - Dereglulation of KRAS expression in prostate cancer**

Abdulaziz Alfahed, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia

17:15 - 17:15 **116P - Targeting mitochondrial biogenesis in the 'CYBRID' model of chronic lymphocytic leukemia for improving cancer related fatigue after chemotherapy**

Lata Singh, AIIMS - All India Institute of Medical Sciences, New Delhi, India



27.02.2024

08:00 - 08:45 **Type: Workshop in collaboration with ESMO YOC** **Room 341**
Title: The contribution of digital technology and AI in early phase trials
Moderation: Elene Mariamidze, Georgia; Rille Pihlak, United Kingdom

08:00 - 08:10 **Digital technology in early phase trials: How do we ensure inclusivity?**
Donna Graham, The Christie NHS Foundation Trust, Manchester, United Kingdom

08:10 - 08:20 **AI in early phase trials: Can implementation of AI improve our trials?**
Andre Freitas, Cancer Research UK Manchester Institute - The University of Manchester, Macclesfield, United Kingdom

08:20 - 08:45 **Q&A and discussion**
All Speakers, ESMO - European Society for Medical Oncology, Lugano, Switzerland

08:45 - 09:15 **Type: Keynote address** **Amphitheatre**
Title: Revisiting the neoantigen approach for cancer immunotherapy **Bordeaux**
Moderation: Lillian Siu, Canada

08:45 - 08:50 **Introduction to the Keynote Speaker**
Lillian Siu, Princess Margaret Cancer Centre, Toronto, Canada

08:50 - 09:15 **Revisiting the neoantigen approach for cancer immunotherapy**
Yardena Samuels, Weizmann Institute of Science, Rehovot, Israel



09:15 - 10:45	Type: Educational session Title: ctDNA applications Moderation: Daniel Shao Weng Tan, Singapore; Anastasios Stathis, Switzerland	Amphitheatre Bordeaux
09:15 - 09:35	Strengths and weaknesses of ctDNA technologies: What does the future hold for liquid biopsy? <u>Marlene Thomas</u> , F. Hoffmann-La Roche AG, Basel, Switzerland	
09:35 - 09:55	MRD testing: Evidence for clinical validity and utility <u>Umberto Malapelle</u> , Università degli Studi di Napoli Federico II - Scuola di Medicina e Chirurgia, Napoli, Italy	
09:55 - 10:15	Implementing broad panel ctDNA testing in a healthcare system: What does it take? <u>Sandi Deans</u> , NHS England, London, United Kingdom	
10:15 - 10:35	ctDNA in drug development: Maximising utility <u>Daniel Shao Weng Tan</u> , NCCS - National Cancer Centre Singapore, Singapore, Singapore	
10:35 - 10:45	Q&A and discussion <u>All Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, Switzerland	
09:15 - 10:45	Type: Educational session Title: Bispecific therapeutics: Moving into the fast lane Moderation: Juanita Lopez, United Kingdom; Jordi Rodon, United States of America	Room 342
09:15 - 09:35	Beyond CD3 bispecifics: Activating NK cells, CD40, CD137 <u>Juanita Lopez</u> , The Royal Marsden Hospital NHS Foundation Trust, Sutton, United Kingdom	
09:35 - 09:55	Beyond PD-1/PDL-1: Engineered PD-1-cis IL2 to overcome T cell exhaustion <u>Ignacio Melero</u> , Clinica Universidad de Navarra, Pamplona, Spain	
09:55 - 10:15	Beyond HLA-restriction: Hapimmune bispecifics <u>Shohei Koide</u> , NYU Langone Medical Center and School of Medicine, New York, United States of America	
10:15 - 10:35	Engineered mRNA and the next generations of bispecific therapeutics <u>Georg Falck</u> , BioNTech SE, Mainz, Germany	
10:35 - 10:45	Q&A and discussion <u>All Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, Switzerland	
10:45 - 11:15	Type: Break Title: Coffee break	Hall Bordeaux



11:15 - 12:45	Type: Special session with Industry Title: Surrogate endpoints in early phase drug development	Amphitheatre Bordeaux
	Moderation: Elena Garralda, Spain; Solange Peters, Switzerland	
11:15 - 11:30	ctDNA to guide decision making in early development <u>Diana Merino Vega</u> , AstraZeneca Pharmaceuticals, LP, Washington, United States of America	
11:30 - 11:45	pCR as a surrogate for early drug development <u>Solange Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland	
11:45 - 12:00	Minimal residual disease as a surrogate for early drug development <u>Davide Rossi</u> , EOC - Amministrazione IOSI, Bellinzona, Switzerland	
12:00 - 12:15	Virtue and challenges of on-treatment biopsies to inform surrogate and exploratory endpoints <u>Paolo Nuciforo</u> , Vall d'Hebron Institute of Oncology - Cellex Center, Barcelona, Spain	
12:15 - 12:45	Panel discussion <u>All Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, Switzerland	
11:15 - 12:45	Type: Educational session Title: Diving into hepatobiliary malignancies	Room 342
	Moderation: Angela Lamarca, Spain; Sophie Postel-Vinay, France	
11:15 - 11:35	Where are we up to with precision medicine in HCC? <u>Pablo Azcue Sanroman</u> , AstraZeneca Plc, Baar, Switzerland	
11:35 - 11:55	Currently available targeted therapies in BTC: Unmet needs <u>Angela Lamarca</u> , Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain	
11:55 - 12:15	New targets for precision medicine in BTC: Where are we going? <u>Antoine Hollebecque</u> , Institut Gustave Roussy, Villejuif, Cedex, France	
12:15 - 12:35	New targeted therapies and IO approaches in hepatobiliary malignancies <u>Jordi Rodon</u> , The University of Texas MD Anderson Cancer Center - Main Building, Houston, United States of America	
12:35 - 12:45	Q&A and discussion <u>All Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, Switzerland	
12:45 - 13:45	Type: Break Title: Lunch & poster viewing	Hall Bordeaux



13:00 - 13:45	Type: Workshop in collaboration with ESMO YOC Title: Increasing efficiency in clinical trial designs Moderation: Elene Mariamidze, Georgia; Rille Pihlak, United Kingdom	Room 341
13:00 - 13:10	Innovative clinical trial design: Patient, scientific, operational and financial considerations <u>Lesley Seymour</u> , Canadian Cancer Trials Group, Kingston, Canada	
13:10 - 13:20	Statistical considerations for efficient trial designs <u>Saskia Litiere</u> , EORTC AISBL/IVZW - European Organisation for Research and Treatment of Cancer, Brussels, Belgium	
13:20 - 13:45	Q&A and discussion <u>All Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, Switzerland	
13:45 - 15:15	Type: Special session with Industry Title: The challenges and opportunities of the EU IVD Regulation Moderation: Fabrice André, France; Carolyn Britten, United States of America	Amphitheatre Bordeaux
13:45 - 14:00	IVDR: Perspective of a pharma company working at the interplay with IVDR <u>Céline Bourguignon</u> , GlaxoSmithKline Pharmaceuticals SA/NV, Wavre, Belgium	
14:00 - 14:15	IVDR implementation: Impacts on early phase oncology research <u>Elena Garralda</u> , Vall d'Hebron University Hospital, Barcelona, Spain	
14:15 - 14:30	IVDR clinical trial impacts and potential solutions: Industry perspective <u>Alison Bond</u> , AMGEN Ltd, Uxbridge, United Kingdom	
14:30 - 14:45	Solutions to IVDR-related challenges for clinical trials and combined studies: Regulator perspective <u>Steve Eglem</u> , Federal Agency for Medicines and Health Products, Brussels, Belgium	
14:45 - 15:15	Panel discussion <u>All Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, Switzerland	



13:45 - 15:15	Type: Educational session Title: Mutant specific inhibitors Moderation: Melissa Johnson, United States of America; Antoine Italiano, France	Room 342
13:45 - 14:05	Taking aim at the undruggable: Mutant-specific KRAS inhibitors, insights and perspectives <u>Melissa Johnson</u> , Sarah Cannon Research Institute-Cancer Centre, Nashville, United States of America	
14:05 - 14:25	Novel mutant-selective EGFR/HER2 kinase inhibitors: Insights and perspectives <u>Capucine Baldini</u> , Institut Gustave Roussy, Villejuif, Cedex, France	
14:25 - 14:45	Targeting PI3KCA in cancer: Are we making headway with mutant specific inhibitors? <u>Antoine Italiano</u> , Institute Bergonié, Bordeaux, France	
14:45 - 15:05	Mutant-selective degradation by kinase-targeting PROTACs: current developments <u>Tanya Dorff</u> , City of Hope Comprehensive Cancer Center, Duarte, United States of America	
15:05 - 15:15	Q&A and discussion <u>All Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, Switzerland	
15:15 - 15:45	Type: Break Title: Coffee break	Hall Bordeaux
15:45 - 17:15	Type: Abstract session Title: Abstract session 2 Moderation: Susan Bates, United States of America; Louise Carter, United Kingdom; Davide Rossi, Switzerland	Amphitheatre Bordeaux
15:45 - 15:51	850 - Low-pass whole genome sequencing (lpWGS) to quantify circulating tumor DNA (ctDNA) burden as a pharmacodynamic response biomarker in patients on early phase trials <u>Aaron Tan</u> , National Cancer Centre Singapore, Singapore, Singapore	
15:51 - 15:57	860 - Serial monitoring of circulating tumor DNA (ctDNA) as a tumor-agnostic biomarker to inform clinical outcomes of patients receiving experimental cancer medicine <u>Kyrillus Shohdy</u> , The University of Manchester & The Christie NHS Foundation Trust, Manchester, Manchester, United Kingdom	
15:57 - 16:07	Invited discussant abstracts 850 and 860 <u>Davide Rossi</u> , EOC - Amministrazione IOSI, Bellinzona, Switzerland	
16:07 - 16:13	150 - Targeting CCNE1-amplified ovarian and endometrial cancers by combined	



inhibition of PKYMT1 and ATR

Fiona Simpkins, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States of America

16:13 - 16:19 **10 - Uncovering new immunotherapy targets with machine learning and ex vivo validation**

Marcellus Augustine, UCL - University College London, London, United Kingdom

16:19 - 16:25 **740 - Highly potent and selective RET inhibitors that overcome adaptive drug resistance**

Li Xing, LexBio Therapeutics, Suzhou, China

16:25 - 16:35 **Invited discussant abstracts 150, 10 and 740**

Susan Bates, Columbia University, New York, United States of America

16:35 - 16:41 **280 - Comparison of prognostic scores in oncology patients participating in phase I clinical trials with immunotherapy**

Paloma Sangro, CCUN - Cancer Center Clinica Universidad de Navarra, Madrid, Spain

16:41 - 16:47 **290 - Clinical characterization of long-term survivors in phase I clinical trials**

Oriol Mirallas, Vall Hebron Institute of Oncology, Barcelona, Spain

16:47 - 16:53 **60 - Subcutaneous fat mass predicts progression-free survival in patients treated with antibody drug conjugates in early phase clinical trials**

Matthieu Delaye, Gustave Roussy, Villejuif, France

16:53 - 17:03 **Invited discussant abstracts 280, 290 and 60**

Louise Carter, The Christie NHS Foundation Trust, Manchester, United Kingdom

17:03 - 17:15 **Q&A**

All Speakers, ESMO - European Society for Medical Oncology, Lugano, Switzerland



28.02.2024

08:30 - 09:15 **Type: Workshop in collaboration with ESMO YOC** **Room 341**
Title: Multidisciplinary trials
Moderation: Elene Mariamidze, Georgia; Rille Pihlak, United Kingdom

08:30 - 08:40 **Delivering excellence in early clinical trials**
Christina Yap, ICR - The Institute of Cancer Research - North Site, Sutton, United Kingdom

08:40 - 08:50 **Ensuring early clinical trial reporting**
Neeltje Steeghs, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

08:50 - 09:15 **Q&A and discussion**
All Speakers, ESMO - European Society for Medical Oncology, Lugano, Switzerland

09:15 - 10:45 **Type: Educational session** **Amphitheatre Bordeaux**
Title: What's new on antibody-drug conjugates?
Moderation: Giuseppe Curigliano, Italy; Toshio Shimizu, Japan

09:15 - 09:35 **Next generation of antibody-drug conjugates: New targets, new linkers and new payloads**
Takashi Kagari, Daiichi Sankyo Co., Ltd., Tokyo, Japan

09:35 - 09:55 **Tumor agnostic development of antibody-drug conjugates**
Barbara Pistilli, Institut Gustave Roussy, Villejuif, Cedex, France

09:55 - 10:15 **Optimising the safety of novel antibody-drug conjugates**
Toshio Shimizu, Wakayama Medical University, Wakayama, Japan

10:15 - 10:35 **Combination of antibody-drug conjugates with other agents**
Giuseppe Curigliano, IEO - Istituto Europeo di Oncologia, Milan, Italy

10:35 - 10:45 **Q&A and discussion**
All Speakers, ESMO - European Society for Medical Oncology, Lugano, Switzerland

10:45 - 11:15 **Type: Break** **Hall Bordeaux**
Title: Coffee Break



11:15 - 12:45	Type: Educational session Title: Adoptive cell therapies in solid tumours Moderation: Evelyn Ullrich, Germany; Ronnie Shapira-Frommer, Israel	Amphitheatre Bordeaux
11:15 - 11:35	Armoured effector cells for treatment of solid tumors <u>Michael O'Dwyer</u> , NUI - National University of Ireland Galway, Galway, Ireland	
11:35 - 11:55	Resistance to CART therapy <u>Patrizia Porazzi</u> , University Of Pennsylvania, Philadelphia, United States of America	
11:55 - 12:15	EGFR-CAR NK against rhabdomyosarcoma and glioblastoma <u>Evelyn Ullrich</u> , Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe-Universität), Frankfurt am Main, Germany	
12:15 - 12:35	TIL therapy in solid tumors <u>Ronnie Shapira-Frommer</u> , The Ella Institute for Treatment and Research of Melanoma and Skin Cancer - Sheba Medical Center, Ramat Gan, Israel	
12:35 - 12:45	Q&A and discussion <u>All Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, Switzerland	
12:45 - 13:30	Type: Workshop in collaboration with ESMO YOC Title: What data I need from the lab before running a phase I Moderation: Elene Mariamidze, Georgia; Rille Pihlak, United Kingdom	Room 341
12:45 - 12:55	Complexities and necessities to move from bench to bedside <u>Tannishtha Reya</u> , HICCC - Herbert Irving Comprehensive Cancer Center - Columbia University, New York, United States of America	
12:55 - 13:05	What should pharmacology tell us before moving a drug from bench to bedside? <u>Sander Bins</u> , Erasmus MC Cancer Institute, Rotterdam, Netherlands	
13:05 - 13:30	Q&A and discussion <u>All Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, Switzerland	
12:45 - 13:30	Type: Break Title: Lunch	Hall Bordeaux



- | | | |
|----------------------|---|----------------------------------|
| 13:30 - 15:00 | Type: Special session with Industry
Title: The quest for dosage and combination optimisation in early drug development
Moderation: Lillian Siu, Canada; Harald Weber, Switzerland | Amphitheatre
Bordeaux |
| 13:30 - 13:45 | Statistical and study design considerations for dose-finding and dose optimisation in early-phase oncology trials
<u>Pavel Mozgunov</u> , University of Cambridge, Cambridge, United Kingdom | |
| 13:45 - 14:00 | Project Optimus: FDA's implementation of the (draft) guidance in practice and implications for drug developers
<u>Sinan Sarac</u> , University of Copenhagen - Faculty of Health and Medical Sciences, Copenhagen, Denmark | |
| 14:00 - 14:15 | Practical approaches to perform dose and combination optimisation in early phase trials, from academic/cooperative group perspective
<u>Stefan Symeonides</u> , Edinburgh Cancer Centre Western General Hospital, Edinburgh, United Kingdom | |
| 14:15 - 14:30 | Role of pharmacogenomics, pharmacokinetics, and pharmacodynamics for dose optimisation in oncology drug development
<u>George P. Patrinos</u> , University of Patras, Patras, Greece | |
| 14:30 - 15:00 | Panel discussion
<u>All Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, Switzerland | |



13:30 - 15:00	Type: Educational session Title: Next generation cell cycle inhibitors and role of biomarker selection Moderation: Timothy Anthony Yap, United States of America; Geoffrey Shapiro, United States of America	Room 342
13:30 - 13:50	Is there a role for biomarker selection for CDK4/6 inhibitors? <u>Stacy Moulder</u> , The University of Texas M. D. Anderson Cancer Center, Houston, United States of America	
13:50 - 14:10	Targeting resistance to CDK4/6 cell cycle inhibitors <u>Geoffrey Shapiro</u> , Dana Farber Cancer Institute, Boston, United States of America	
14:10 - 14:30	Use of ctDNA for the management of patients on CDK4/6 inhibitors <u>Nicholas Turner</u> , The Royal Marsden Hospital - Chelsea, London, United Kingdom	
14:30 - 14:50	Emergence of next generation CDK4-selective and CDK2-selective inhibitors in the clinic <u>Timothy Anthony Yap</u> , The University of Texas MD Anderson Cancer Center - Main Building, Houston, United States of America	
14:50 - 15:00	Q&A and discussion <u>All Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, Switzerland	